In their study, a triazine-modified dendrimer G5-DAT 66 was synthesized and used as a vector for TRAIL gene therapy in vitro and in vivo, and their results suggested that triazine-modified dendrimer has promising potential for TRAIL gene therapy in osteosarcoma [7]; but these treatments achieved only marginal improvements in comparison to conventional chemotherapy. This evidence concerns the gene TNFSF10 and osteosarcoma.